Plain-English translation of NCT05116384 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Atrial fibrillation is an irregular heartbeat that can cause symptoms and complications. This trial is testing whether combining two procedures — standard heart ablation (which isolates the pulmonary veins) plus renal artery denervation (a procedure that reduces nerve signals to the kidneys) — works better than heart ablation alone. Recent research suggests that calming the nervous system's activity on the heart may help prevent the irregular heartbeat from returning.
Standard heart ablation alone doesn't always work long-term, and many patients need repeated procedures. This treatment addresses a different cause of atrial fibrillation — overactivity of the nervous system — to see if it can improve success rates and reduce recurrence.
You likely qualify if…
You likely don't qualify if…
You will undergo heart ablation to isolate the pulmonary veins (the standard treatment). Half of participants will also receive the kidney nerve procedure on the same day. You will have a small implantable monitor placed under your skin to track your heart rhythm. You will need to attend follow-up appointments and comply with post-procedure care instructions for at least one year to see if the combination treatment prevents your atrial fibrillation from returning.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States